These results indicate that DEG-KRAS is broadly effective across multiple KRAS-mutant pancreatic cancer cell lines and that its antiproliferative effects are potentiated in contexts where adhesion-mediated survival signals are disrupted. The gene discussed is KRAS; the disease is pancreatic neoplasm.